Pages that link to "Q62730269"
Jump to navigation
Jump to search
The following pages link to Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A (Q62730269):
Displaying 27 items.
- A Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic α-Exosite Binding Region (Q27659624) (← links)
- Accurate reproduction of 161 small-molecule complex crystal structures using the EUDOC program: expanding the use of EUDOC to supramolecular chemistry (Q28469227) (← links)
- Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design (Q28750297) (← links)
- Small molecules showing significant protection of mice against botulinum neurotoxin serotype A (Q28752594) (← links)
- Metal Ion Modeling Using Classical Mechanics (Q30363020) (← links)
- Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A (Q33294825) (← links)
- Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease (Q33722985) (← links)
- Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease (Q33850913) (← links)
- Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors (Q34074218) (← links)
- Analysis of botulinum neurotoxin serotype A metalloprotease inhibitors: analogs of a chemotype for therapeutic  development in the context of a three-zone pharmacophore (Q34317228) (← links)
- Retracted: Small-Molecule Quinolinol Inhibitor Identified Provides Protection against BoNT/A in Mice (Q34447906) (← links)
- An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. (Q35669634) (← links)
- Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity (Q35746555) (← links)
- Magnesium-cationic dummy atom molecules enhance representation of DNA polymerase beta in molecular dynamics simulations: improved accuracy in studies of structural features and mutational effects (Q35768246) (← links)
- Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E. (Q36430556) (← links)
- Convenient Synthesis of a Library of Discrete Hydroxamic Acids Using the Hydroxythiophenol (Marshall) Resin (Q36600345) (← links)
- Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A. (Q36895179) (← links)
- Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A (Q37274652) (← links)
- Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry (Q37323247) (← links)
- Targeting botulinum A cellular toxicity: a prodrug approach (Q37432753) (← links)
- Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A. (Q40139133) (← links)
- Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. (Q45951244) (← links)
- Low-mass molecular dynamics simulation for configurational sampling enhancement: More evidence and theoretical explanation (Q47155240) (← links)
- Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFRα1 and Small-Molecule Ligands (Q57489646) (← links)
- Targeting Metalloenzymes for Therapeutic Intervention (Q59830619) (← links)
- Increasing synthetic efficiency via direct C–H functionalization: formal synthesis of an inhibitor of botulinum neurotoxin (Q64958869) (← links)
- In silico drug discovery: solving the "target-rich and lead-poor" imbalance using the genome-to-drug-lead paradigm (Q79448420) (← links)